ロード中...

Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer

One of the major recent clinical advances in cancer treatment is the use of antiangiogenic drugs such as bevacizumab, sorafenib, and sunitinib. Bevacizumab, the monoclonal anti-VEGF antibody, has been approved for the first line treatment of metastatic breast cancer (MBC) when combined with taxane....

詳細記述

保存先:
書誌詳細
出版年:Breast
第一著者: Kerbel, Robert S.
フォーマット: Artigo
言語:Inglês
出版事項: 2009
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4540343/
https://ncbi.nlm.nih.gov/pubmed/19914541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0960-9776(09)70271-1
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!